Mutations in NFE2L2 (Nrf2) are not frequently described as common in bladder cancer; however, analysis of TCGA data of activating mutations found in the Nrf2/pathway are common in carcinogen-exposed cancers (including bladder) and are associated with aggressive disease [36]. Here, NFE2L2 is linked to cancer.